Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Price History  |  Ratios  |  Insiders

Breaking & Recent News Lantern Pharma Inc LTRN

Healthcare Biotechnology
Lantern Pharma Inc. focuses on the discovery and development of oncology drug in India. Its product pipeline comprises LP-300, which is in phase 2 clinical trial in combination therapy for never-smokers with non-small cell lung cancer adenocarcinoma; LP-184, which is in phase 1 clinical trial for the treatment of solid tumor, such as pancreatic, breast, bladder, and lung cancers, as well as... see more

Recent & Breaking News (NDAQ:LTRN)

Lantern Pharma Announces Establishing an A.I. Center of Excellence in India to Industrialize the RADR® Platform and Accelerate Global Development Opportunities with BioPharma Companies

Business Wire 2 days ago

Lantern Pharma Reports Additional Positive LP-184 Phase 1a Results Showing Durable Disease Control in Heavily Pre-Treated Advanced Cancer Patients as Company Advances Precision Oncology Program into Multiple Biomarker-Guided Phase 1b/2 Trials

Business Wire December 3, 2025

Lantern Pharma Reports Third Quarter 2025 Financial Results and Provides Business Updates

Business Wire November 13, 2025

Lantern Pharma to Report Third Quarter 2025 Operating & Financial Results on November 13th, 2025 at 9:00 a.m. ET

Business Wire November 6, 2025

Lantern Pharma to Present AI-Driven Cancer Drug Development & Research Platforms at Inaugural AI for Biology and Medicine Symposium at UNT

Business Wire October 30, 2025

Lantern Pharma Presents LP-284 Clinical Data at 25th LL&M Congress, Highlighting Complete Response in Therapeutically Exhausted DLBCL Patient & Therapeutic Potential in Advanced B-Cell Cancers.

Business Wire October 28, 2025

Lantern Pharma to Present at the ThinkEquity Conference in NYC on October 30, 2025

Business Wire October 24, 2025

Lantern Pharma's LP-184 Phase 1a Clinical Trial Achieves All Primary Endpoints with Robust Safety Profile and Promising Antitumor Activity in Multiple Advanced Solid Tumors

Business Wire September 16, 2025

Lantern Pharma Announces Completion of Type C Meeting with FDA, Providing Clarity on Regulatory Pathway for Pediatric CNS Cancer Trial

Business Wire September 3, 2025

Lantern Pharma Reports Second Quarter 2025 Financial Results and Business Updates

Business Wire August 13, 2025

Lantern Pharma's Subsidiary, Starlight Therapeutics, Announces U.S. Food and Drug Administration Clearance of IND for Phase Ib/2a Glioblastoma Multiforme (GBM) Trial

Business Wire August 6, 2025

Lantern Pharma Announces Public Release of Transformative, Advanced AI Module for Blood-Brain Barrier Permeability Prediction, predictBBB.ai(TM)

Business Wire August 4, 2025

Lantern Pharma Completes Targeted Enrollment for Lung Cancer Phase 2 Harmonic(TM) Clinical Trial in Japan for LP-300

Business Wire July 31, 2025

Lantern Pharma Announces Appointment of Dr. Lee Schalop to Board of Directors

Business Wire July 28, 2025

Lantern Pharma Reports Complete Response in Heavily Pre-Treated Lymphoma Patient with LP-284 in Phase 1 Clinical Trial

Business Wire July 23, 2025

Lantern Pharma Secures EU Patent Allowance for LP-284, Bolstering Global IP Position for AI-Developed Cancer Therapy

Business Wire July 21, 2025

Lantern Pharma Unveils Groundbreaking AI-Powered Module to Predict Activity and Efficacy of Combination Regimens in Clinical Cancer Treatment

Business Wire July 15, 2025

Lung Cancer Patient in Lantern Pharma's Harmonic Trial Shows Durable Complete Response in Target Cancer Lesions with Survival Continuing for Nearly Two Years

Business Wire June 16, 2025

Lantern Pharma's LP-184 Shows Promising In Vivo Activity in Atypical Teratoid Rhabdoid Tumors (ATRT) at SNO Pediatric Conference, Further Validating Rare Pediatric Disease Designation and Pathway to Clinical Trials

Business Wire May 29, 2025

Lantern Pharma Reports First Quarter 2025 Financial Results and Business Updates

Business Wire May 15, 2025

Podcasts